Related Experiment Video
Updated: Aug 15, 2025

Sequencing of Bacterial Microflora in Peripheral Blood: our Experience with HIV-infected Patients
Published on: June 11, 2011
Breakthrough Infections: Clinical Profile and Outcomes of COVID-19 Vaccinated and Unvaccinated People From a Tertiary
Praveen R Shahapur1, Roopa Shahapur2, Smitha Bagali1
1Microbiology, Shri B.M. Patil Medical College Hospital and Research Centre, BLDE (DU), Vijayapura, IND.
Insights
COVID-19 vaccines may not prevent infection but protect against severe illness. Vaccinated individuals had higher viral cycle threshold values, suggesting lower viral load and reduced transmission risk.
Area of Science:
- Virology
- Epidemiology
- Immunology
Background:
- Breakthrough COVID-19 infections challenge vaccine efficacy.
- Understanding clinical outcomes in vaccinated vs. unvaccinated populations is crucial.
Purpose of the Study:
- Evaluate COVID-19 breakthrough infections.
- Compare clinical profiles and outcomes of vaccinated and unvaccinated individuals.
Main Methods:
- Retrospective observational study (March-April 2021).
- Data collection: socio-demographics, COVID-19 profiles, clinical outcomes, vaccination status.
- Next-generation sequencing (NGS) for variant screening.
Main Results:
- 103 patients: 32% vaccinated, 68% unvaccinated.
- All hospitalizations (29.2%) and deaths (60% among hospitalized) occurred in unvaccinated individuals.
- Vaccinated individuals showed higher Cycle threshold (Ct) values (indicating lower viral load) compared to unvaccinated.
- Delta variant was predominant (76.7%).
Conclusions:
- Vaccination appears to protect against severe COVID-19, despite not preventing infection.
- Higher Ct values in vaccinated individuals suggest reduced viral load and potential for minimized transmission.
- Further research into vaccine effectiveness against emerging variants is warranted.
Abstract:
Introduction Despite the availability of a vaccine and extensive vaccination, breakthrough infections are commonly noted, which is jeopardizing the vaccine-based protection against COVID-19. The present study aims to evaluate COVID-19 breakthrough infections and to compare the clinical profile and outcomes of the vaccinated and unvaccinated populations. Methods A retrospective observational study was conducted for two months (March-April 2021), and all cases reported during the study period were included in the study. Socio-demographic details, COVID-19 profiles, clinical outcomes, vaccination statuses, and types of vaccine were collected from the patients. Further, COVID-19-positive samples were screened for lineages using next-generation sequencing (NGS). Results Of the total 103 patients included in the study, 79 (76.7%) were symptomatic and 24 (23.3%) were asymptomatic. Only 32% were vaccinated and 68% were unvaccinated. 29.2% were hospitalized due to COVID-19 and all of them were unvaccinated. The mortality among hospitalized patients was extremely high (60%). The time to positivity after complete vaccination was noted to be 37.09±23.74 days. The unvaccinated study participants showed lower Cycle threshold (Ct) values (E Gene/N Gene: 17.38±4.53) as compared to the vaccinated people (E Gene/N Gene: 22±4.25). The Delta (B. 1.1. 629) (76.7%) was the predominant variant among the study population followed by AY.4 (20.4%) and Kappa (2.9%) variants. Conclusion Although the vaccination does not restrict/avoid infection, it appears to protect the vaccinated people from severe forms of COVID-19. Also, the higher Ct values among vaccinated people indicate that the viral load among such people may be lower and, therefore, minimizes viral transmission.
More Related Videos
Related Concept Videos
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care
Factors Affecting the Risk of Infection
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
Acute Pyelonephritis II: Diagnostic Studies and Management
Pneumonia III: Complications and Assessment
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Healthcare Associated Infections I: Iatrogenic, Exogenic and Endogenic
HAIs significantly increase the cost of health care. Extended stays in healthcare institutions, increased disability, increased costs of medications, including specialized antibiotics, and prolonged recovery times add to the patient's expenses and the healthcare institution and funding bodies.

